Simultaneous and Rapid Determination of Six Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Using HPLC-MS/MS

Overview

Journal Int J Anal Chem

Publisher Wiley

Specialty Chemistry

Date 2021 Sep 27

PMID 34567122

Citations 1

Authors

Yanping Liu

Hua Liu

Zhewei Xia

Zhipeng Wang

Yunlei Yun

Guanying Zhang

Lifeng Huang

Shouhong Gao

Wansheng Chen

Affiliations

Soon will be listed here.

Abstract

Objective: To develop a new method for quantitatively analyzing six tyrosine kinase inhibitors (gefitinib, erlotinib, icotinib, afatinib, osimertinib, and crizotinib) used in the treatment of non-small cell lung cancer (NSCLC) by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Methods: The analytes were detected in the selected reaction monitoring mode on a triple quadrupole mass spectrometer with the positive ionization mode. Carbamazepine was utilized as the internal standard. The pretreatment of the plasma sample was completed based on protein precipitation with acetonitrile, and the analytes were separated on an Agilent Zorbax SB-C18 reversed-phase column (2.1 mm × 100 mm, 3.5 m, Agilent, USA) using gradient elution. The mobile phase consisted of 0.1% formic acid in water (phase A) and 0.1% formic acid in acetonitrile (phase B). The flow rate was 0.3 mL/min, and the injection volume was 5 L. The column temperature was set and maintained at 35°C.

Results: The calibration curves were linear over the range from 5.0 to 1000.0 ng/mL for gefitinib, crizotinib, and osimertinib; from 50.0 to 4000.0 ng/mL for icotinib and erlotinib; and from 5.0 to 400.0 ng/mL for afatinib. Linear correlation coefficients were >0.990 for all regression curves. The intra- and interday accuracy and precision of the method were within ±15.0% and not more than 15.0%, respectively. The mean recovery of all the analytes ranged from 70.18% to 110.76%, the matrix effect was from 88.85% to 127.58%, and stability was within ±15.0%.

Conclusion: This newly developed method was sensitive, simple, and robust and could be used in therapeutic drug monitoring of six tyrosine kinase inhibitors in NSCLC patients.

Citing Articles

Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring.

Chen L, Zhang Y, Zhang Y, Wang W, Sun D, Li P J Pharm Anal. 2024; 14(4):100899.

PMID: 38634061 PMC: 11022103. DOI: 10.1016/j.jpha.2023.11.006.

References

Yu H, Steeghs N, Nijenhuis C, Schellens J, Beijnen J, Huitema A . Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014; 53(4):305-25. DOI: 10.1007/s40262-014-0137-2. View

Zhang W, Zhang Y, Zhao Q, Liu X, Chen L, Pan H . Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. J Thorac Dis. 2020; 12(3):639-650. PMC: 7139014. DOI: 10.21037/jtd.2019.12.115. View

He Y, Zhou L, Gao S, Yin T, Tu Y, Rayford R . Development and validation of a sensitive LC-MS/MS method for simultaneous determination of eight tyrosine kinase inhibitors and its application in mice pharmacokinetic studies. J Pharm Biomed Anal. 2017; 148:65-72. PMC: 8519014. DOI: 10.1016/j.jpba.2017.09.013. View

Ueno N, Banno S, Endo Y, Tamura M, Sugaya K, Hashigaki S . Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings. Jpn J Clin Oncol. 2019; 49(7):676-686. DOI: 10.1093/jjco/hyz049. View

Hayashi H, Kita Y, Iihara H, Yanase K, Ohno Y, Hirose C . Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer. Biomed Chromatogr. 2015; 30(7):1150-1154. DOI: 10.1002/bmc.3642. View

Huynh H, Pressiat C, Sauvageon H, Madelaine I, Maslanka P, Lebbe C . Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS. Ther Drug Monit. 2016; 39(1):43-54. DOI: 10.1097/FTD.0000000000000357. View

Reis R, Labat L, Allard M, Boudou-Rouquette P, Chapron J, Bellesoeur A . Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell.... J Pharm Biomed Anal. 2018; 158:174-183. DOI: 10.1016/j.jpba.2018.05.052. View

Barta J, Powell C, Wisnivesky J . Global Epidemiology of Lung Cancer. Ann Glob Health. 2019; 85(1). PMC: 6724220. DOI: 10.5334/aogh.2419. View

Shaw A, Kim D, Nakagawa K, Seto T, Crino L, Ahn M . Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25):2385-94. DOI: 10.1056/NEJMoa1214886. View

10.

Almomen A, Maher H, Alzoman N, Shehata S, Alsubaie A . Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats. PeerJ. 2020; 8:e9881. PMC: 7518156. DOI: 10.7717/peerj.9881. View

11.

Wang Z, Yang Y, Zhang F, Li M, Chen J, Man H . A direct, sensitive and efficient method for determination of alpha-fluoro-beta-alanine in urine: Evaluating the influence of magnesium isoglycyrrhizinate on excretion in rat model. J Chromatogr B Analyt Technol Biomed Life Sci. 2018; 1102-1103:17-22. DOI: 10.1016/j.jchromb.2018.10.016. View

12.

Solassol I, Pinguet F, Quantin X . FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced -Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. Biomolecules. 2019; 9(11). PMC: 6921037. DOI: 10.3390/biom9110668. View

13.

Sakamoto S, Sato K, Takita Y, Izumiya Y, Kumagai N, Sudo K . ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. Invest New Drugs. 2020; 38(6):1687-1695. DOI: 10.1007/s10637-020-00946-x. View

14.

Merienne C, Rousset M, Ducint D, Castaing N, Titier K, Molimard M . High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS. J Pharm Biomed Anal. 2017; 150:112-120. DOI: 10.1016/j.jpba.2017.11.060. View

15.

Zhang H, Li Q, Zhu X, Wu M, Li C, Li X . Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects. Front Pharmacol. 2018; 9:849. PMC: 6090208. DOI: 10.3389/fphar.2018.00849. View

16.

Kulkarni N, Parvathaneni V, Shukla S, Barasa L, Perron J, Yoganathan S . Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment. Eur J Pharm Sci. 2019; 133:145-159. DOI: 10.1016/j.ejps.2019.03.026. View

17.

Lucas C, Martin J . Pharmacokinetic-Guided Dosing of New Oral Cancer Agents. J Clin Pharmacol. 2017; 57 Suppl 10:S78-S98. DOI: 10.1002/jcph.937. View

18.

Groenland S, Geel D, Janssen J, de Vries N, Rosing H, Beijnen J . Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients. Clin Pharmacol Ther. 2020; 109(2):394-402. PMC: 7891593. DOI: 10.1002/cpt.1989. View

19.

Kawata T, Higashimori M, Itoh Y, Tomkinson H, Johnson M, Tang W . Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. 2019; 83(5):849-858. PMC: 6458983. DOI: 10.1007/s00280-019-03788-4. View

20.

Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P . Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clin Pharmacokinet. 2016; 56(3):235-250. PMC: 5315738. DOI: 10.1007/s40262-016-0440-1. View